Primary Sclerosing Cholangitis Market

Key Players: AbbVie (US), Gilead Sciences (US), Bristol-Myers Squibb (US), Novartis (CH), Merck & Co. (US), Amgen (US), Roche (CH), Eli Lilly and Company (US), Pfizer (US)

Primary Sclerosing Cholangitis Market

Primary Sclerosing Cholangitis Market Research Report By Treatment (Medications, Surgery, Endoscopic Retrograde Cholangiopancreatography (ERCP)), By Diagnostic Procedures (Magnetic Resonance Cholangiopancreatography (MRCP), Liver Biopsy, Blood Tests), By Disease Severity (Early Stage, Intermediate Stage, Advanced Stage), By Comorbidities (Ulcerative Colitis, Crohn's Disease, Autoimmune Hepatitis), By Pipeline Therapies (FXR Agonists, IL-12/23 Inhibitors, JAK Inhibitors) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035
ID: MRFR/HC/25425-HCR
128 Pages
Rahul Gotadki
Last Updated: May 15, 2026
Request Free Sample

Primary Sclerosing Cholangitis Market Summary

As per Market Research Future analysis, the Primary Sclerosing Cholangitis Market Size was estimated at 0.16 USD Billion in 2024. The Primary Sclerosing Cholangitis industry is projected to grow from USD 0.1679 Billion in 2025 to USD 0.2711 Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 4.91% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The Primary Sclerosing Cholangitis Market is poised for growth driven by advancements in treatment and increasing awareness.

  • The market is experiencing rising awareness and diagnosis of Primary Sclerosing Cholangitis Market, particularly in North America.
  • Advancements in therapeutic development are shaping the landscape, with a notable focus on personalized medicine.
  • Medications remain the largest segment, while surgery is emerging as the fastest-growing treatment option.
  • The increasing incidence of Primary Sclerosing Cholangitis Market and growing investment in research and development are key drivers of market expansion.

Market Size & Forecast

2024 Market Size 0.16 (USD Billion)
2035 Market Size 0.2711 (USD Billion)
CAGR (2025 - 2035) 4.91%

Major Players

AbbVie (US), Gilead Sciences (US), Bristol-Myers Squibb (US), Novartis (CH), Merck & Co. (US), Amgen (US), Roche (CH), Eli Lilly and Company (US), Pfizer (US)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

Primary Sclerosing Cholangitis Market Trends

The Primary Sclerosing Cholangitis Market is currently experiencing a notable evolution, driven by a combination of increasing awareness and advancements in therapeutic options. As healthcare professionals and patients alike become more informed about this rare liver disease, the demand for effective treatments appears to be on the rise. This heightened awareness is likely to foster a more proactive approach to diagnosis and management, potentially leading to improved patient outcomes. Furthermore, ongoing research into the underlying mechanisms of Primary Sclerosing Cholangitis Market may yield novel therapeutic targets, enhancing the overall treatment landscape. In addition to awareness, the market is also influenced by the growing interest in personalized medicine. Tailoring treatment strategies to individual patient profiles could enhance efficacy and minimize adverse effects. Pharmaceutical companies are increasingly focusing on developing targeted therapies that address the specific needs of patients with Primary Sclerosing Cholangitis Market. This trend suggests a shift towards more sophisticated treatment paradigms, which may ultimately reshape the market dynamics. As the landscape continues to evolve, stakeholders must remain vigilant to adapt to these changes and leverage emerging opportunities.

Rising Awareness and Diagnosis

The increasing recognition of Primary Sclerosing Cholangitis Market among healthcare providers is leading to more timely diagnoses. Enhanced educational initiatives and resources are contributing to this trend, which may result in earlier intervention and improved patient management.

Advancements in Therapeutic Development

Innovations in drug development are paving the way for new treatment options in the Primary Sclerosing Cholangitis Market. Research into novel therapies, including biologics and small molecules, is expected to expand the therapeutic arsenal available to clinicians.

Focus on Personalized Medicine

The shift towards personalized medicine is becoming more pronounced within the Primary Sclerosing Cholangitis Market. Tailoring treatments to individual patient characteristics may enhance therapeutic outcomes and reduce the risk of adverse effects.

Primary Sclerosing Cholangitis Market Drivers

Emerging Biologics and Novel Therapies

The emergence of biologics and novel therapeutic agents is transforming the treatment paradigm for Primary Sclerosing Cholangitis Market. Recent advancements in biotechnology have led to the development of targeted therapies that may offer improved efficacy and safety profiles compared to traditional treatments. The Primary Sclerosing Cholangitis Market is witnessing a surge in clinical trials aimed at evaluating these innovative therapies, which could potentially enhance patient outcomes. As more data becomes available, healthcare providers may increasingly adopt these new treatment modalities, thereby driving market growth. Furthermore, the potential for combination therapies that leverage the strengths of multiple agents could further stimulate interest and investment in the Primary Sclerosing Cholangitis Market.

Rising Patient Advocacy and Support Groups

The increasing presence of patient advocacy and support groups is playing a crucial role in shaping the Primary Sclerosing Cholangitis Market. These organizations are dedicated to raising awareness about PSC, providing education, and advocating for research funding. Their efforts may lead to greater recognition of the disease among healthcare professionals and the general public, potentially resulting in earlier diagnosis and treatment. Furthermore, patient advocacy groups often collaborate with pharmaceutical companies to facilitate clinical trials and gather patient-reported outcomes, which can inform the development of new therapies. As these groups continue to grow in influence, they may significantly impact the trajectory of the Primary Sclerosing Cholangitis Market.

Regulatory Support for Innovative Treatments

Regulatory bodies are increasingly providing support for the development of innovative treatments for Primary Sclerosing Cholangitis Market, which may bolster the Primary Sclerosing Cholangitis Market. Initiatives aimed at expediting the approval process for promising therapies could encourage pharmaceutical companies to invest in this area. The potential for fast-track designations and priority review vouchers may incentivize the development of novel agents targeting PSC. As regulatory frameworks evolve to accommodate advancements in medical science, the market could see a proliferation of new treatment options that enhance patient care. This supportive environment may ultimately lead to a more robust and competitive Primary Sclerosing Cholangitis Market.

Growing Investment in Research and Development

Investment in research and development (R&D) for Primary Sclerosing Cholangitis Market is gaining momentum, which could significantly impact the Primary Sclerosing Cholangitis Market. Pharmaceutical companies are increasingly allocating resources to explore novel treatment options and improve existing therapies. This trend is likely fueled by the recognition of PSC as a complex disease with diverse manifestations, necessitating a multifaceted approach to treatment. As R&D efforts intensify, the market may witness the introduction of groundbreaking therapies that address the underlying mechanisms of PSC. Additionally, collaborations between academic institutions and industry players may foster innovation, further propelling the growth of the Primary Sclerosing Cholangitis Market.

Increasing Incidence of Primary Sclerosing Cholangitis

The rising incidence of Primary Sclerosing Cholangitis Market (PSC) appears to be a pivotal driver for the Primary Sclerosing Cholangitis Market. Recent epidemiological studies indicate that the prevalence of PSC is on the rise, particularly among individuals with inflammatory bowel disease. This increase in diagnosed cases is likely to spur demand for effective treatment options, thereby expanding the market. As healthcare providers become more adept at recognizing the symptoms and complications associated with PSC, the number of patients seeking medical intervention is expected to grow. Consequently, pharmaceutical companies may find it beneficial to invest in research and development to address this unmet medical need, potentially leading to innovative therapies that could reshape the landscape of the Primary Sclerosing Cholangitis Market.

Market Segment Insights

By Treatment: Medications (Largest) vs. Surgery (Fastest-Growing)

Within the Primary Sclerosing Cholangitis Market (PSC) market, medications constitute the largest segment, capturing a significant market share due to the increasing prevalence of PSC and ongoing advances in pharmaceutical treatments. Drugs targeting the inflammatory process and cholestatic pruritus have gained traction, making medications the preferred initial intervention for many patients. Surgical options, while important, hold a smaller share but are growing rapidly as surgical techniques improve and care teams increasingly recognize the need for surgical intervention in advanced disease stages. In terms of growth trends, the treatment landscape for PSC is evolving. Medications are seeing stable demand driven by continuous research, while surgery is experiencing faster growth particularly due to new minimally invasive techniques, which promise to yield better outcomes and shorter recovery times. Moreover, the role of ERCP remains crucial for both diagnosis and therapeutic intervention, providing an additional growth avenue as awareness and effectiveness continue to rise.

Medications (Dominant) vs. Surgery (Emerging)

Medications for Primary Sclerosing Cholangitis Market are currently the dominant treatment option, focusing on managing symptoms and slowing disease progression. This segment benefits from a range of therapies, including immunosuppressants and newer pharmacologic agents that address cholestasis. They are often seen as a first-line approach, favored for their non-invasive nature and ease of administration. On the other hand, surgery is emerging as a viable option for patients with severe disease or complications. Surgical procedures like liver transplantation are increasingly recognized for their role in improving long-term outcomes. The expanding evidence base supporting surgical interventions, paired with technological advances in surgical applications, are driving a noticeable shift in treatment paradigms, positioning surgery as an essential alternative in the progression of PSC management.

By Diagnostic Procedures: Magnetic Resonance Cholangiopancreatography (MRCP) (Largest) vs. Blood Tests (Fastest-Growing)

In the Primary Sclerosing Cholangitis Market, the Magnetic Resonance Cholangiopancreatography (MRCP) segment stands out as the largest component, accounting for a significant share thanks to its non-invasive nature and ability to provide detailed images of the bile ducts. On the other hand, Blood Tests are emerging as the fastest-growing segment due to their accessible nature and advancing techniques that enhance diagnostic accuracy. This distribution reflects the evolving preferences of medical practitioners and patients towards less invasive and more convenient diagnostic options.

MRCP (Dominant) vs. Blood Tests (Emerging)

Magnetic Resonance Cholangiopancreatography (MRCP) is the dominant diagnostic procedure in the Primary Sclerosing Cholangitis Market, favored for its ability to visualize the biliary tree without the need for invasive procedures. This method offers detailed insights, helping physicians make informed decisions about treatment strategies. Conversely, Blood Tests, labeled as the emerging segment, are gaining traction due to innovations in biomarker identification and the integration of advanced technologies, such as AI-driven analytics. The rapid adoption of blood tests is driven by their minimal risk, ease of collection, and the potential for large-scale screening, thereby appealing to a broader patient demographic.

By Disease Severity: Early Stage (Largest) vs. Advanced Stage (Fastest-Growing)

In the Primary Sclerosing Cholangitis Market (PSC) market, the distribution of disease severity segments shows that the 'Early Stage' segment holds the largest share, primarily due to the increasing diagnosis rates facilitated by advanced imaging techniques and awareness among healthcare providers. Conversely, 'Advanced Stage' is witnessing the fastest growth, attributed to the escalation in severe disease cases that necessitate aggressive treatment options and increasing research focus on advanced therapeutic interventions.

Disease Severity: Early Stage (Dominant) vs. Advanced Stage (Emerging)

The 'Early Stage' segment in the Primary Sclerosing Cholangitis Market is characterized by a significant number of diagnosed cases, where patients exhibit milder symptoms and often have a prolonged course of the disease. This segment benefits from routine monitoring and management strategies, which contribute to its dominance in the market. In contrast, the 'Advanced Stage' segment is emerging rapidly, driven by the urgent demand for innovative therapies and clinical trials focusing on late-stage interventions. Advanced cases pose substantial clinical challenges, making this segment appealing for pharmaceutical development and research initiatives. The disparity in characteristics between these segments emphasizes the need for tailored treatment approaches to optimize patient outcomes.

By Comorbidities: Ulcerative Colitis (Largest) vs. Crohn's Disease (Fastest-Growing)

In the Primary Sclerosing Cholangitis Market, Ulcerative Colitis has emerged as the largest comorbidity segment. This condition significantly drives patient prevalence and treatment demand, as many individuals with Primary Sclerosing Cholangitis Market present symptoms related to Ulcerative Colitis. The focus on tailored therapies for this comorbidity enhances treatment outcomes and has garnered significant attention from pharmaceutical companies. Conversely, Crohn's Disease is identified as the fastest-growing segment in this market. Increased awareness and diagnosis of Crohn's alongside Primary Sclerosing Cholangitis Market have led to a notable surge in related treatment options. Ongoing research and development focus on disease-modifying therapies which are expected to further accelerate growth and establish a stronger presence in the treatment landscape.

Ulcerative Colitis (Dominant) vs. Autoimmune Hepatitis (Emerging)

Ulcerative Colitis stands as the dominant comorbidity within the Primary Sclerosing Cholangitis Market due to its established association with liver disease and significant healthcare resource utilization. The high prevalence of Ulcerative Colitis among Primary Sclerosing Cholangitis Market patients necessitates a coordinated treatment approach that encompasses inflammatory bowel disease management alongside liver health. In contrast, Autoimmune Hepatitis is viewed as an emerging segment with increasing recognition in clinical settings. As awareness grows regarding its interplay with Primary Sclerosing Cholangitis Market, innovative treatment options are being explored. Although currently not as dominant as Ulcerative Colitis, Autoimmune Hepatitis exhibits a rising interest in research, indicating potential opportunities for future market expansion.

By Pipeline Therapies: FXR Agonists (Largest) vs. JAK Inhibitors (Fastest-Growing)

Within the Primary Sclerosing Cholangitis Market, FXR Agonists currently dominate the pipeline therapies segment, commanding the largest share. Their established presence and efficacy in treating cholestatic liver diseases have positioned them favorably among healthcare providers and patients alike. JAK Inhibitors, on the other hand, are emerging rapidly, showcasing significant potential due to their innovative approach in managing inflammation and fibrosis associated with PSC, thus attracting increasing interest from pharmaceutical researchers and investors.

FXR Agonists (Dominant) vs. JAK Inhibitors (Emerging)

FXR Agonists are recognized for their ability to regulate bile acid levels and promote liver health, making them a dominant choice in the Primary Sclerosing Cholangitis Market treatment landscape. Their mechanism of action directly addresses the underlying pathology of PSC, leading to improved patient outcomes. In contrast, JAK Inhibitors represent an emerging therapeutic class, leveraging their impact on inflammatory pathways to deliver promising results. With ongoing clinical trials demonstrating their efficacy, JAK Inhibitors are gaining traction and are expected to significantly influence treatment paradigms in the near future.

Get more detailed insights about Primary Sclerosing Cholangitis Market
Request Free Sample

Regional Insights

North America : Leading Market for Innovation

North America is the largest market for Primary Sclerosing Cholangitis Market (PSC), accounting for approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, high prevalence of autoimmune diseases, and significant investments in research and development. Regulatory support from agencies like the FDA further catalyzes market growth, with a focus on innovative therapies and clinical trials driving demand. The United States is the primary contributor to this Primary Sclerosing Cholangitis Market, with key players such as AbbVie, Gilead Sciences, and Bristol-Myers Squibb leading the competitive landscape. Canada also plays a significant role, albeit smaller, with a growing emphasis on patient access to novel treatments. The presence of these major pharmaceutical companies ensures a robust pipeline of therapies aimed at managing PSC effectively.

Europe : Emerging Market with Potential

Europe is the second-largest market for Primary Sclerosing Cholangitis Market, holding approximately 30% of the global market share. The region is characterized by increasing awareness of PSC and a rising number of clinical trials. Regulatory bodies like the European Medicines Agency (EMA) are actively promoting research initiatives, which are expected to enhance treatment options and patient outcomes in the coming years. Leading countries in this market include Germany, France, and the United Kingdom, where healthcare systems are increasingly prioritizing rare diseases. The competitive landscape features major players such as Novartis and Roche, who are investing in innovative therapies. The collaboration between public health organizations and pharmaceutical companies is fostering a conducive environment for market growth.

Asia-Pacific : Emerging Powerhouse in Healthcare

The Asia-Pacific region is witnessing significant growth in the Primary Sclerosing Cholangitis Market, accounting for about 15% of the global share. Factors such as increasing healthcare expenditure, rising awareness of autoimmune diseases, and improving access to advanced medical treatments are driving this growth. Countries like China and India are emerging as key players, supported by government initiatives aimed at enhancing healthcare infrastructure and patient care. China is leading the market in this region, with a growing number of clinical trials and collaborations with global pharmaceutical companies. The competitive landscape is evolving, with local firms beginning to invest in research and development. The presence of international players like Merck & Co. and Amgen further strengthens the market, ensuring a diverse range of treatment options for patients.

Middle East and Africa : Resource-Rich Frontier for Healthcare

The Middle East and Africa region is gradually emerging in the Primary Sclerosing Cholangitis Market, holding around 10% of the global market share. The growth is driven by increasing healthcare investments, rising awareness of PSC, and the establishment of specialized healthcare facilities. Regulatory frameworks are evolving, with governments focusing on improving healthcare access and treatment options for rare diseases. Leading countries in this region include South Africa and the UAE, where healthcare systems are becoming more robust. The competitive landscape is still developing, with a mix of local and international players. Companies are beginning to recognize the potential in this market, leading to increased collaborations and investments aimed at addressing the unmet needs of PSC patients.

Primary Sclerosing Cholangitis Market Regional Image

Key Players and Competitive Insights

The Primary Sclerosing Cholangitis Market (PSC) market is characterized by a complex interplay of competitive dynamics, driven by the increasing prevalence of the disease and the urgent need for effective therapies. Major players such as AbbVie (US), Gilead Sciences (US), and Bristol-Myers Squibb (US) are at the forefront, each adopting distinct strategies to enhance their market presence. AbbVie (US) focuses on innovation through its robust pipeline of immunology products, while Gilead Sciences (US) emphasizes strategic partnerships to bolster its research capabilities. Bristol-Myers Squibb (US) is leveraging its expertise in oncology to explore novel therapeutic approaches for PSC, thereby shaping a competitive environment that prioritizes advanced treatment modalities and collaborative research efforts.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The PSC market appears moderately fragmented, with a blend of established pharmaceutical giants and emerging biotech firms. This structure allows for a diverse range of treatment options, although the influence of key players remains substantial, as they drive innovation and set industry standards.
In August AbbVie (US) announced a strategic collaboration with a leading biotech firm to develop a novel therapy targeting PSC. This partnership is expected to accelerate the development timeline and enhance the therapeutic options available to patients, reflecting AbbVie's commitment to addressing unmet medical needs in this area. The collaboration signifies a shift towards more integrated approaches in drug development, potentially leading to more effective treatments.
In September Gilead Sciences (US) launched a new clinical trial aimed at evaluating the efficacy of its investigational drug for PSC. This initiative underscores Gilead's focus on expanding its therapeutic portfolio and demonstrates its proactive stance in addressing the challenges posed by PSC. The trial's outcomes could significantly influence treatment paradigms and reinforce Gilead's position as a leader in the market.
In July Bristol-Myers Squibb (US) unveiled a new research initiative aimed at understanding the underlying mechanisms of PSC. This initiative not only highlights the company's commitment to scientific exploration but also positions it to potentially discover novel therapeutic targets. By investing in foundational research, Bristol-Myers Squibb is likely to enhance its competitive edge in the long term, paving the way for innovative treatment solutions.
As of October the PSC market is witnessing trends such as digitalization, sustainability, and the integration of artificial intelligence in drug development processes. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a pronounced shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition may redefine how companies approach market entry and product development, ultimately benefiting patients through improved therapeutic options.

Key Companies in the Primary Sclerosing Cholangitis Market include

Industry Developments

The Primary Sclerosing Cholangitis Market (PSC) market is poised for significant growth, driven by rising disease prevalence, advancements in treatment options, and increasing awareness. In 2023, the market was valued at USD 7.05 billion, and it is projected to reach USD 15.51 billion by 2032, exhibiting a CAGR of 9.17%.Recent developments include the approval of new therapies, such as obeticholic acid and cenicriviroc, which offer improved outcomes for patients. Research into the underlying causes and potential cures for PSC is ongoing, with promising developments in stem cell therapy and gene editing.

Future Outlook

Primary Sclerosing Cholangitis Market Future Outlook

The Primary Sclerosing Cholangitis Market is projected to grow at a 4.91% CAGR from 2025 to 2035, driven by advancements in treatment options, increasing awareness, and rising patient populations.

New opportunities lie in:

  • Development of targeted biologic therapies for enhanced patient outcomes. Expansion of telehealth services for remote patient monitoring and consultations. Investment in AI-driven diagnostic tools to improve early detection rates.

By 2035, the Primary Sclerosing Cholangitis Market is expected to demonstrate robust growth and innovation.

Market Segmentation

Primary Sclerosing Cholangitis Market Treatment Outlook

  • Medications
  • Surgery
  • Endoscopic Retrograde Cholangiopancreatography (ERCP)

Primary Sclerosing Cholangitis Market Comorbidities Outlook

  • Ulcerative Colitis
  • Crohn's Disease
  • Autoimmune Hepatitis

Primary Sclerosing Cholangitis Market Disease Severity Outlook

  • Early Stage
  • Intermediate Stage
  • Advanced Stage

Primary Sclerosing Cholangitis Market Pipeline Therapies Outlook

  • FXR Agonists
  • IL-12/23 Inhibitors
  • JAK Inhibitors

Primary Sclerosing Cholangitis Market Diagnostic Procedures Outlook

  • Magnetic Resonance Cholangiopancreatography (MRCP)
  • Liver Biopsy
  • Blood Tests

Report Scope

MARKET SIZE 2024 0.16(USD Billion)
MARKET SIZE 2025 0.1679(USD Billion)
MARKET SIZE 2035 0.2711(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 4.91% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled AbbVie (US), Gilead Sciences (US), Bristol-Myers Squibb (US), Novartis (CH), Merck & Co. (US), Amgen (US), Roche (CH), Eli Lilly and Company (US), Pfizer (US)
Segments Covered Treatment, Diagnostic Procedures, Disease Severity, Comorbidities, Pipeline Therapies, Regional
Key Market Opportunities Advancements in targeted therapies and personalized medicine enhance treatment options in the Primary Sclerosing Cholangitis Market.
Key Market Dynamics Rising demand for targeted therapies drives innovation and competition in the Primary Sclerosing Cholangitis market.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the projected market valuation for Primary Sclerosing Cholangitis in 2035?

The projected market valuation for Primary Sclerosing Cholangitis in 2035 is 0.2711 USD Billion.

What was the overall market valuation for Primary Sclerosing Cholangitis in 2024?

The overall market valuation for Primary Sclerosing Cholangitis in 2024 was 0.16 USD Billion.

What is the expected CAGR for the Primary Sclerosing Cholangitis Market from 2025 to 2035?

The expected CAGR for the Primary Sclerosing Cholangitis Market during the forecast period 2025 - 2035 is 4.91%.

Which companies are key players in the Primary Sclerosing Cholangitis Market?

Key players in the Primary Sclerosing Cholangitis Market include AbbVie, Gilead Sciences, Bristol-Myers Squibb, Novartis, Merck & Co., Amgen, Roche, Eli Lilly and Company, and Pfizer.

What are the main treatment segments in the Primary Sclerosing Cholangitis Market?

The main treatment segments include Medications, Surgery, and Endoscopic Retrograde Cholangiopancreatography (ERCP), with valuations ranging from 0.04 to 0.14 USD Billion.

How do diagnostic procedures contribute to the Primary Sclerosing Cholangitis Market?

Diagnostic procedures such as Magnetic Resonance Cholangiopancreatography (MRCP), Liver Biopsy, and Blood Tests contribute with valuations between 0.04 and 0.1211 USD Billion.

What is the market segmentation based on disease severity for Primary Sclerosing Cholangitis?

Market segmentation based on disease severity includes Early Stage, Intermediate Stage, and Advanced Stage, with valuations from 0.05 to 0.1 USD Billion.

What comorbidities are associated with Primary Sclerosing Cholangitis?

Comorbidities associated with Primary Sclerosing Cholangitis include Ulcerative Colitis, Crohn's Disease, and Autoimmune Hepatitis, with valuations between 0.04 and 0.1 USD Billion.

What pipeline therapies are being developed for Primary Sclerosing Cholangitis?

Pipeline therapies for Primary Sclerosing Cholangitis include FXR Agonists, IL-12/23 Inhibitors, and JAK Inhibitors, with valuations ranging from 0.03 to 0.085 USD Billion.

How does the market for Primary Sclerosing Cholangitis compare to previous years?

The market for Primary Sclerosing Cholangitis is expected to grow from 0.16 USD Billion in 2024 to 0.2711 USD Billion by 2035, indicating a positive trend.

Author
Author
Author Profile
Rahul Gotadki LinkedIn
Research Manager
He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.
Get In Touch
Leave a Comment

Research Approach

Secondary Research

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, clinical publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA), European Medicines Agency (EMA), American Association for the Study of Liver Diseases (AASLD), European Association for the Study of the Liver (EASL), American College of Gastroenterology (ACG), National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Center for Biotechnology Information (NCBI/PubMed), Centers for Disease Control and Prevention (CDC), World Health Organization (WHO) Global Health Observatory, Orphanet, National Organization for Rare Disorders (NORD), PSC Partners Seeking a Cure, PSC Support UK, ClinicalTrials.gov, EU Clinical Trials Register, and national health ministry reports from key markets. These sources were used to collect epidemiology statistics, regulatory approval data, clinical safety and efficacy studies, diagnostic procedure volumes, comorbidity association rates (particularly Inflammatory Bowel Disease correlations), and competitive landscape analysis for FXR agonists, IL-12/23 inhibitors, JAK inhibitors, and other emerging pipeline therapies.

Primary Research

Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. Pharmaceutical manufacturers that were developing PSC therapeutics, diagnostic equipment manufacturers (MRCP imaging systems), and contract research organizations (CROs) that specialized in hepatology trials were among the supply-side sources. These sources included CEOs, VPs of Clinical Development, regulatory affairs heads, and commercial directors. Demand-side sources included board-certified hepatologists, gastroenterologists who specialized in cholestatic liver diseases, transplant surgeons, medical directors of liver transplant centers, and procurement leads from academic medical centers, tertiary care hospitals, and specialized hepatology clinics. Primary research confirmed the influence of clinical trial timelines, reimbursement dynamics for orphan drugs, and patient advocacy on treatment adoption, while also validating market segmentation across treatment modalities (medications, surgery, ERCP), diagnostic procedures (MRCP, liver biopsy, blood tests), disease severity stages, comorbidity profiles, and pipeline therapy categories.

Primary Respondent Breakdown:

By Designation: C-level Primaries (28%), Director Level (32%), Others (40%)

By Region: North America (38%), Europe (29%), Asia-Pacific (22%), Rest of World (11%)

Market Size Estimation

Global market valuation was derived through revenue mapping, procedure volume analysis, and epidemiology-based patient pool estimation. The methodology included:

Identification of 35+ key manufacturers and developers across North America, Europe, Asia-Pacific, and Latin America focusing on PSC and cholestatic liver disease therapeutics

Product mapping across medications (ursodeoxycholic acid, obeticholic acid, off-label immunosuppressants), surgical interventions (liver transplantation, biliary drainage procedures), and endoscopic treatments (ERCP with balloon dilation/stenting)

Diagnostic procedure analysis covering MRCP imaging volumes, liver biopsy rates, and emerging non-invasive biomarker blood tests (ALP, GGT, IgG4, ELF test, FibroScan)

Pipeline assessment of FXR agonists (e.g., cilofexor, tropifexor), IL-12/23 inhibitors, JAK inhibitors, and anti-fibrotic agents in Phase II/III development

Analysis of reported and modeled annual revenues specific to PSC indications and associated comorbidity management (Ulcerative Colitis, Crohn's Disease)

Coverage of manufacturers and developers representing 65-70% of global market share in 2024

Extrapolation using bottom-up (prevalence patient pool × diagnosis rate × treatment penetration × ASP by country) and top-down (manufacturer revenue validation, orphan drug pricing analysis) approaches to derive segment-specific valuations across treatment types, diagnostic methods, disease severity stages, and pipeline therapy categories

This methodology accounts for PSC's characteristics as a rare disease (orphan indication) with strong IBD associations, complex diagnostic pathways involving advanced imaging, and an evolving treatment landscape shifting from supportive care to targeted therapies.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.